PGI develops non-invasive, low-cost ventilation device

Naina Mishra

Chandigarh, February 5

The Anaesthesia Department of the PGIMER has developed TrueOxy High Flow Nasal Cannula (HFNC) device, a cost-effective solution for non-invasive ventilation. This indigenous device boasts of an automatic airflow temperature oxygen control system, ensuring precise patient care.

The project was developed under Prof Goverdhan Dutt Puri, former Head of the Department of Anaesthesia.

High flow nasal cannula device

• TrueOxy delivers precise blend of air and oxygen, ensuring optimal oxygenation levels
• Beneficial in managing acute hypoxemic respiratory failure, post-surgical respiratory failure
• Doesn’t require invasive intubation; patients often find HFNC therapy more comfortable

With a focus on versatility, TrueOxy operates in a dual mode – airline and blower — catering to both adult and paediatric patients. The incorporation of advanced safety features, along with easy device and patient access, distinguishes it in the medical landscape.

The TrueOxy device delivers a precise blend of air and oxygen, ensuring optimal oxygenation levels. This can be particularly beneficial in managing acute hypoxemic respiratory failure, post-surgical respiratory failure and other conditions without resorting to invasive intubation. Patients often find HFNC therapy more comfortable than intubation. The high flow of warm and humidified oxygen enhances patient tolerance, potentially reducing the reluctance or discomfort associated with traditional ventilation methods. The HFNC therapy has shown promise in managing obstructive sleep apnea, providing a non-invasive option for patients with this condition.

Materials and equipment, including TrueOxy , fluke gas flow analyser and medical air & oxygen sources, contribute to its lightweight and portable design.

The development of this innovative device has reached significant milestones. Patent filing is underway with TIFAC, DST, New Delhi, showcasing the potential for broader impact. Phase I and phase II performance testing at BID-Hub, PGIMER, has been successfully completed, highlighting the device’s efficacy.

TrueOxy has achieved certification on IEC/ISO standards from a regional NABL laboratory, emphasising its adherence to international quality benchmarks. Currently undergoing clinical testing at the PGIMER, this device holds promise in transforming respiratory care, marking a crucial step forward in medical innovation.